Evozyne
Chicago, US · Founded 2020 · 55 employees on LinkedIn · 7 known investors
Find your way into Evozyne
134 people in our graph share verified history with the Evozyne team — schools, employers, funds. One of them is your warm intro.
Cat Wuunlockedknows Aris Theologis · together at Anthropic (overlapped)
×11knows the team · via Anthropic
Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases. The company develops novel biologics and a pipeline of engineered proteins aimed at clinical use.
Founders & leadership
AT
Aris TheologisinFounding Chief Business Officer2021–2024Aris Theologis is an executive with over 15 years of experience in operations, business development, strategy, and finance across life sciences and healthcare companies; he is Executive Officer and Director at Evozyne, which develops engineered protein therapeutics using an AI platform for immune-mediated diseases.
DP
Darien ParhadExecutive
PJ
Patrick J. MorrisExecutive
MY
Marc YoskowitzinCEO
RR
Rama RanganathanNamed on SEC filing
Board
JS
Jeffrey S. AroninBoard director
AG
Antonio GraciasinBoard directorFounder, Chief Executive Officer & Chief Investment Officer at Valor Equity Partners
Investors · 7
Paragon Biosciences LLC✓ verifiedChicago
OrbiMedNew York · $1M – $75M
Fidelity InvestmentsreportedBoston
NVenturesreportedSanta Clara
NVIDIAreportedSanta Clara
Valor Equity PartnersreportedChicagovia Antonio Gracias · board
Also in the syndicate · 1
Valor Equity Partner
Reported raises · per SEC filings
Form D private placements$144.4M disclosed across 3 rounds · 2020–2023
▶$81MraisedSep 2023 · 29 investors · BiotechnologyRule 506(b)
▶$81MraisedSep 2023 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antonio GraciasDirector
- Jeffrey S. AroninExecutive Officer, Director
- Aris TheologisExecutive Officer
- Darien ParhadExecutive Officer
- Jude M. SullivanExecutive Officer
- Aleina LeeExecutive Officer
- Rama RanganathanExecutive Officer, Director
- Patrick J. MorrisExecutive Officer, Director
- Mike GamsonExecutive Officer, Director
- Matthew RizzoDirector
- Arjun RallapalliExecutive Officer
- Offering amount
- $100M
- Amount sold
- $81M
- Sales commissions
- $2M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$54.2MraisedApr 2021 · 12 investors · BiotechnologyRule 506(b)
▶$54.2MraisedApr 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aris TheologisExecutive Officer, Director
- Rama RanganathanExecutive Officer, Director
- Darien ParhadExecutive Officer
- Patrick J. MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Antonio GraciasDirector
- Offering amount
- $59.2M
- Amount sold
- $54.2M
- Sales commissions
- $1.6M
- Placement agents
- Paragon Health Capital
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$9.2MraisedMay 2020 · 2 investors · BiotechnologyRule 506(b)
▶$9.2MraisedMay 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aris TheologisExecutive Officer, Director
- Rama RanganathanExecutive Officer, Director
- Darien ParhadExecutive Officer
- Jeffrey S. AroninExecutive Officer, Director
- Antonio GraciasDirector
- Patrick J MorrisExecutive Officer, Director
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- First sale
- Apr 2020
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Evozyne do?
- Evozyne designs and builds engineered protein therapeutics using an AI-native platform, focusing on treatments for immune-mediated diseases. The company develops novel biologics and a pipeline of engineered proteins aimed at clinical use.
- Who are Evozyne's investors?
- Evozyne's investors include Paragon Biosciences LLC, OrbiMed, Fidelity Investments, NVentures, NVIDIA, Valor Equity Partners.
- How much funding has Evozyne raised?
- Evozyne has disclosed $144.4M raised across 3 rounds.
- Where is Evozyne headquartered?
- Evozyne is headquartered in Chicago, US.